Corruption and Fraud Send Chill Through China's Pharma

Mara is a contributing editor with Science based in Shanghai.

Last month, the Chinese government accused GlaxoSmithKline (GSK) of bribing officials and others to ease GSK drug sales. With four executives in prison, the ongoing investigation may jeopardize big pharma's burgeoning R&D operations in China. But while multinationals may consider stricter controls on their China operations, few expect the companies to pull out of the growing market.

Read the Full Text. (Login may be required.)

Posted in Asia/Pacific, Health